Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies Public Deposited

http://ir.library.oregonstate.edu/concern/articles/m900nw34q

Descriptions

Attribute NameValues
Creator
Abstract or Summary
  • Two identical single-ascending-dose studies evaluated the safety and pharmacokinetics (PK) of AVI-6002 and AVI-6003, two experimental combinations of phosphorodiamidate morpholino oligomers with positive charges (PMOplus) that target viral mRNA encoding Ebola virus and Marburg virus proteins, respectively. Both AVI-6002 and AVI-6003 were found to suppress disease in virus-infected nonhuman primates in previous studies. AVI-6002 (a combination of AVI-7537 and AVI-7539) or AVI-6003 (a combination of AVI-7287 and AVI-7288) were administered as sequential intravenous (i.v.) infusions of a 1:1 fixed dose ratio of the two subcomponents. In each study, 30 healthy male and female subjects between 18 and 50 years of age were enrolled in six-dose escalation cohorts of five subjects each and received a single i.v. infusion of active study drug (0.005, 0.05, 0.5, 1.5, 3, and 4.5 mg/kg per component) or placebo in a 4:1 ratio. Both AVI-6002 and AVI-6003 were safe and well tolerated at the doses studied. A maximum tolerated dose was not observed in either study. The four chemically similar PMOplus components exhibited generally similar PK profiles. The mean peak plasma concentration and area under the concentration-time curve values of the four components exhibited dose-proportional PK. The estimated plasma half-life of all four components was 2 to 5 h. The safety of the two combinations and the PK of the four components were similar, regardless of the target RNA sequence.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Heald, A. E., Iversen, P. L., Saoud, J. B., Sazani, P., Charleston, J. S., Axtelle, T., & Wong, M. (2014, August 25). Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies. Antimicrobial Agents and Chemotherapy, 58(11). doi:10.1128/AAC.03442-14
Series
Keyword
Rights Statement
Publisher
Peer Reviewed
Language
Replaces
Additional Information
  • description.provenance : Submitted by Sue Kunda (sue.kunda@oregonstate.edu) on 2014-10-21T19:32:49Z No. of bitstreams: 1 IversonPatrickLSafetyPharmacokineticProfiles.pdf: 755168 bytes, checksum: 29c83b56f029ed02dafb8c68f5aad797 (MD5)
  • description.provenance : Approved for entry into archive by Sue Kunda(sue.kunda@oregonstate.edu) on 2014-10-21T19:33:13Z (GMT) No. of bitstreams: 1 IversonPatrickLSafetyPharmacokineticProfiles.pdf: 755168 bytes, checksum: 29c83b56f029ed02dafb8c68f5aad797 (MD5)
  • description.provenance : Made available in DSpace on 2014-10-21T19:33:13Z (GMT). No. of bitstreams: 1 IversonPatrickLSafetyPharmacokineticProfiles.pdf: 755168 bytes, checksum: 29c83b56f029ed02dafb8c68f5aad797 (MD5) Previous issue date: 2014-08-25

Relationships

In Administrative Set:
Last modified: 07/27/2017

Downloadable Content

Download PDF
Citations:

EndNote | Zotero | Mendeley

Items